Clinical Trial Update: Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose [Phase 4]

View source ↗

Summary

Phase 4 trial assessing how long the MenACWY meningococcal conjugate vaccine remains immunogenic five years after vaccination and the immune response to a boost…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenACWY Conjugate Vaccine (Meningococcal conjugate vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 4 | Status: COMPLETED | Results posted: 2014-08-15